These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 25260897)

  • 1. (-)-Epigallocatechin-3-gallate inhibits entry of hepatitis B virus into hepatocytes.
    Huang HC; Tao MH; Hung TM; Chen JC; Lin ZJ; Huang C
    Antiviral Res; 2014 Nov; 111():100-11. PubMed ID: 25260897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.
    Calland N; Albecka A; Belouzard S; Wychowski C; Duverlie G; Descamps V; Hober D; Dubuisson J; Rouillé Y; Séron K
    Hepatology; 2012 Mar; 55(3):720-9. PubMed ID: 22105803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry.
    Ciesek S; von Hahn T; Colpitts CC; Schang LM; Friesland M; Steinmann J; Manns MP; Ott M; Wedemeyer H; Meuleman P; Pietschmann T; Steinmann E
    Hepatology; 2011 Dec; 54(6):1947-55. PubMed ID: 21837753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigallocatechin gallate inhibits hepatitis B virus infection in human liver chimeric mice.
    Lai YH; Sun CP; Huang HC; Chen JC; Liu HK; Huang C
    BMC Complement Altern Med; 2018 Sep; 18(1):248. PubMed ID: 30189898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide.
    Kaneko M; Watashi K; Kamisuki S; Matsunaga H; Iwamoto M; Kawai F; Ohashi H; Tsukuda S; Shimura S; Suzuki R; Aizaki H; Sugiyama M; Park SY; Ito T; Ohtani N; Sugawara F; Tanaka Y; Mizokami M; Sureau C; Wakita T
    J Virol; 2015 Dec; 89(23):11945-53. PubMed ID: 26378168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies to inhibit entry of HBV and HDV into hepatocytes.
    Urban S; Bartenschlager R; Kubitz R; Zoulim F
    Gastroenterology; 2014 Jul; 147(1):48-64. PubMed ID: 24768844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ergosterol peroxide inhibits HBV infection by inhibiting the binding of the pre-S1 domain of LHBsAg to NTCP.
    Huang H; Huang HC; Chiou WC; Lin LC; Chen JC; Liu HK; Lai YH; Huang C
    Antiviral Res; 2021 Nov; 195():105184. PubMed ID: 34627935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust Human and Murine Hepatocyte Culture Models of Hepatitis B Virus Infection and Replication.
    Qiao L; Sui J; Luo G
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30232184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Green tea extract and its major component epigallocatechin gallate inhibits hepatitis B virus in vitro.
    Xu J; Wang J; Deng F; Hu Z; Wang H
    Antiviral Res; 2008 Jun; 78(3):242-9. PubMed ID: 18313149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP.
    Iwamoto M; Watashi K; Tsukuda S; Aly HH; Fukasawa M; Fujimoto A; Suzuki R; Aizaki H; Ito T; Koiwai O; Kusuhara H; Wakita T
    Biochem Biophys Res Commun; 2014 Jan; 443(3):808-13. PubMed ID: 24342612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unusual Features of Sodium Taurocholate Cotransporting Polypeptide as a Hepatitis B Virus Receptor.
    Li J; Zong L; Sureau C; Barker L; Wands JR; Tong S
    J Virol; 2016 Sep; 90(18):8302-13. PubMed ID: 27384660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus.
    Volz T; Allweiss L; Ben MBarek M; Warlich M; Lohse AW; Pollok JM; Alexandrov A; Urban S; Petersen J; Lütgehetmann M; Dandri M
    J Hepatol; 2013 May; 58(5):861-7. PubMed ID: 23246506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells.
    König A; Yang J; Jo E; Park KHP; Kim H; Than TT; Song X; Qi X; Dai X; Park S; Shum D; Ryu WS; Kim JH; Yoon SK; Park JY; Ahn SH; Han KH; Gerlich WH; Windisch MP
    J Hepatol; 2019 Aug; 71(2):289-300. PubMed ID: 31077792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP).
    Watashi K; Sluder A; Daito T; Matsunaga S; Ryo A; Nagamori S; Iwamoto M; Nakajima S; Tsukuda S; Borroto-Esoda K; Sugiyama M; Tanaka Y; Kanai Y; Kusuhara H; Mizokami M; Wakita T
    Hepatology; 2014 May; 59(5):1726-37. PubMed ID: 24375637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin 6 inhibits HBV entry through NTCP down regulation.
    Bouezzedine F; Fardel O; Gripon P
    Virology; 2015 Jul; 481():34-42. PubMed ID: 25765005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro Infection with Hepatitis B Virus Using Differentiated Human Serum Culture of Huh7.5-NTCP Cells without Requiring Dimethyl Sulfoxide.
    Le C; Sirajee R; Steenbergen R; Joyce MA; Addison WR; Tyrrell DL
    Viruses; 2021 Jan; 13(1):. PubMed ID: 33445753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (-)-Epigallocatechin-3-gallate inhibits the replication cycle of hepatitis C virus.
    Chen C; Qiu H; Gong J; Liu Q; Xiao H; Chen XW; Sun BL; Yang RG
    Arch Virol; 2012 Jul; 157(7):1301-12. PubMed ID: 22491814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity.
    Shimura S; Watashi K; Fukano K; Peel M; Sluder A; Kawai F; Iwamoto M; Tsukuda S; Takeuchi JS; Miyake T; Sugiyama M; Ogasawara Y; Park SY; Tanaka Y; Kusuhara H; Mizokami M; Sureau C; Wakita T
    J Hepatol; 2017 Apr; 66(4):685-692. PubMed ID: 27890789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a mass spectrometric screening assay for hepatitis B virus entry inhibitors.
    Goh B; Choi J; Kang JA; Park SG; Seo J; Kim TY
    J Pharm Biomed Anal; 2020 Jan; 178():112959. PubMed ID: 31722821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na(+)-dependent taurocholate cotransporting polypeptide activity.
    Wang XJ; Hu W; Zhang TY; Mao YY; Liu NN; Wang SQ
    Antiviral Res; 2015 Aug; 120():140-6. PubMed ID: 26086883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.